{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:50:57Z","timestamp":1740167457330,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40121-023-00875-1","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:02:09Z","timestamp":1696525329000},"page":"2485-2494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin"],"prefix":"10.1007","volume":"12","author":[{"given":"Razieh","family":"Kebriaei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacinda C.","family":"Abdul-Mutakabbir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle C.","family":"Stamper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine L.","family":"Lev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-043X","authenticated-orcid":false,"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"875_CR1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/BF01967563","volume":"8","author":"PE Reynolds","year":"1989","unstructured":"Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989;8:943\u201350.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 4","key":"875_CR2","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.ijid.2010.05.009","volume":"14","author":"S Stefani","year":"2010","unstructured":"Stefani S, Goglio A. Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance. Int J Infect Dis. 2010;14(Suppl 4):S19-22.","journal-title":"Int J Infect Dis"},{"key":"875_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1172\/JCI18535","volume":"111","author":"FD Lowy","year":"2003","unstructured":"Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest. 2003;111:1265\u201373.","journal-title":"J Clin Invest"},{"key":"875_CR4","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1172\/JCI68834","volume":"124","author":"S Gardete","year":"2014","unstructured":"Gardete S, Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest. 2014;124:2836\u201340.","journal-title":"J Clin Invest"},{"key":"875_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1128\/CMR.00042-09","volume":"23","author":"BP Howden","year":"2010","unstructured":"Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23:99\u2013139.","journal-title":"Clin Microbiol Rev"},{"key":"875_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/ajhp\/62.11.1145","volume":"62","author":"CA Schriever","year":"2005","unstructured":"Schriever CA, Fern\u00e1ndez C, Rodvold KA, Danziger LH. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm. 2005;62:1145\u201358.","journal-title":"Am J Health Syst Pharm"},{"key":"875_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/cid\/cir340","volume":"53","author":"A Dhand","year":"2011","unstructured":"Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal \u03b2-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53:158\u201363.","journal-title":"Clin Infect Dis"},{"issue":"910","key":"875_CR8","first-page":"e1","volume":"27","author":"BJ Werth","year":"2021","unstructured":"Werth BJ, Ashford NK, Penewit K, et al. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2021;27(910):e1-910.e8.","journal-title":"Clin Microbiol Infect"},{"key":"875_CR9","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1128\/AAC.00223-11","volume":"55","author":"NN Mishra","year":"2011","unstructured":"Mishra NN, McKinnell J, Yeaman MR, et al. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55:4012\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"875_CR10","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1086\/648473","volume":"200","author":"S-J Yang","year":"2009","unstructured":"Yang S-J, Kreiswirth BN, Sakoulas G, et al. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis. 2009;200:1916\u201320.","journal-title":"J Infect Dis"},{"key":"875_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1128\/JCM.00660-07","volume":"46","author":"G Sakoulas","year":"2008","unstructured":"Sakoulas G, Rose W, Rybak MJ, et al. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol. 2008;46:220\u20134.","journal-title":"J Clin Microbiol"},{"key":"875_CR12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1128\/AAC.50.3.1079-1082.2006","volume":"50","author":"L Cui","year":"2006","unstructured":"Cui L, Tominaga E, Neoh H, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:1079\u201382.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"875_CR13","doi-asserted-by":"publisher","first-page":"ii15","DOI":"10.1093\/jac\/dki005","volume":"55","author":"A Malabarba","year":"2005","unstructured":"Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005;55(Suppl 2):ii15-20.","journal-title":"J Antimicrob Chemother"},{"key":"875_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/(SICI)1098-1128(199701)17:1<69::AID-MED3>3.0.CO;2-R","volume":"17","author":"A Malabarba","year":"1997","unstructured":"Malabarba A, Nicas TI, Thompson RC. Structural modifications of glycopeptide antibiotics. Med Res Rev. 1997;17:69\u2013137.","journal-title":"Med Res Rev"},{"key":"875_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/23744235.2017.1296968","volume":"49","author":"RP Dash","year":"2017","unstructured":"Dash RP, Babu RJ, Srinivas NR. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infect Dis (Lond). 2017;49:483\u201392.","journal-title":"Infect Dis (Lond)"},{"key":"875_CR16","first-page":"82","volume":"74","author":"X Xhemali","year":"2019","unstructured":"Xhemali X, Smith JR, Kebriaei R, et al. Evaluation of dalbavancin alone and in combination with \u03b2-lactam antibiotics against resistant phenotypes of Staphylococcus aureus. J Antimicrob Chemother. 2019;74:82\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"875_CR17","doi-asserted-by":"publisher","unstructured":"Kebriaei R, Rice SA, Stamper KC, Rybak MJ. Dalbavancin alone and in combination with ceftaroline against four different phenotypes of Staphylococcus aureus in a simulated pharmacodynamic\/pharmacokinetic model. Antimicrob Agents Chemother. 2019;63:e01743-18. https:\/\/doi.org\/10.1128\/aac.01743-18.","DOI":"10.1128\/aac.01743-18"},{"key":"875_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/antibiotics9100696","volume":"9","author":"JC Abdul-Mutakabbir","year":"2020","unstructured":"Abdul-Mutakabbir JC, Kebriaei R, Stamper KC, et al. Dalbavancin, vancomycin and daptomycin alone and in combination with cefazolin against resistant phenotypes of Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model. Antibiotics. 2020;9:696.","journal-title":"Antibiotics"},{"key":"875_CR19","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 30th Edition. Clinical & Laboratory Standards Institute. M100. 2020. https:\/\/clsi.org\/all-free-resources\/. Accessed 1 Apr 2020."},{"key":"875_CR20","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1093\/jac\/dkaa237","volume":"75","author":"R Kebriaei","year":"2020","unstructured":"Kebriaei R, Rice SA, Singh NB, et al. Combinations of (lipo)glycopeptides with \u03b2-lactams against MRSA: susceptibility insights. J Antimicrob Chemother. 2020;75:2894\u2013901.","journal-title":"J Antimicrob Chemother"},{"key":"875_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/526772","volume":"46","author":"M Billeter","year":"2008","unstructured":"Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis. 2008;46:577\u201383.","journal-title":"Clin Infect Dis"},{"key":"875_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","volume":"4","author":"JR Smith","year":"2015","unstructured":"Smith JR, Roberts KD, Rybak MJ. Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against gram-positive infections. Infect Dis Ther. 2015;4:245\u201358.","journal-title":"Infect Dis Ther"},{"key":"875_CR23","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1128\/AAC.00247-06","volume":"50","author":"M Benvenuto","year":"2006","unstructured":"Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"875_CR24","unstructured":"Anon. easySpiral Dilute\u2014Dilutor and plater | INTERSCIENCE. https:\/\/www.interscience.com\/en\/products\/automatic-platers\/easyspiral-dilute. Accessed 31 Jul 2023."},{"key":"875_CR25","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1128\/AAC.35.12.2505","volume":"35","author":"BL Lee","year":"1991","unstructured":"Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother. 1991;35:2505\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"875_CR26","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","volume":"48","author":"KL LaPlante","year":"2004","unstructured":"LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004;48:4665\u201372.\u00a0https:\/\/doi.org\/10.1128\/AAC.48.12.4665-4672.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"875_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00386-19","author":"R Kebriaei","year":"2019","unstructured":"Kebriaei R, Rice SA, Stamper KC, et al. Daptomycin dose-ranging evaluation with single-dose versus multidose ceftriaxone combinations against Streptococcus mitis\/oralis in an ex vivo simulated endocarditis vegetation model. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.00386-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"875_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00315-18","author":"R Kebriaei","year":"2018","unstructured":"Kebriaei R, Rice SA, Singh KV, et al. Influence of inoculum effect on the efficacy of daptomycin monotherapy and in combination with \u03b2-lactams against daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.00315-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"875_CR29","doi-asserted-by":"publisher","first-page":"e02260","DOI":"10.1128\/AAC.02260-20","volume":"65","author":"PG Cojutti","year":"2021","unstructured":"Cojutti PG, Rinaldi M, Zamparini E, et al. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections. Antimicrob Agents Chemother. 2021;65:e02260-e2320.","journal-title":"Antimicrob Agents Chemother"},{"key":"875_CR30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/jac\/dkr551","volume":"67","author":"JM Wenisch","year":"2012","unstructured":"Wenisch JM, Meyer B, Fuhrmann V, et al. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2012;67:977\u201383.","journal-title":"J Antimicrob Chemother"},{"key":"875_CR31","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1093\/jac\/dkz226","volume":"74","author":"JR Lenhard","year":"2019","unstructured":"Lenhard JR, Bulman ZP. Inoculum effect of \u03b2-lactam antibiotics. J Antimicrob Chemother. 2019;74:2825\u201343. https:\/\/doi.org\/10.1093\/jac\/dkz226.","journal-title":"J Antimicrob Chemother"},{"key":"875_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/clinids\/11.3.361","volume":"11","author":"I Brook","year":"1989","unstructured":"Brook I. Inoculum effect. Rev Infect Dis. 1989;11:361\u20138.","journal-title":"Rev Infect Dis"},{"key":"875_CR33","doi-asserted-by":"publisher","unstructured":"Loffredo MR, Savini F, Bobone S, et al. Inoculum effect of antimicrobial peptides. 2020: 2020.08.21.260620. https:\/\/doi.org\/10.1101\/2020.08.21.260620v1.","DOI":"10.1101\/2020.08.21.260620v1"},{"key":"875_CR34","doi-asserted-by":"publisher","first-page":"9661","DOI":"10.1038\/s41598-018-28006-8","volume":"8","author":"M Kussmann","year":"2018","unstructured":"Kussmann M, Obermueller M, Berndl F, et al. Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Sci Rep. 2018;8:9661.","journal-title":"Sci Rep"},{"key":"875_CR35","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1517\/14656566.2015.1075508","volume":"16","author":"S Ramdeen","year":"2015","unstructured":"Ramdeen S, Boucher HW. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Expert Opin Pharmacother. 2015;16:2073\u201381.","journal-title":"Expert Opin Pharmacother"},{"key":"875_CR36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jac\/dkw416","volume":"72","author":"G Aktas","year":"2017","unstructured":"Aktas G, Derbentli S. In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains. J Antimicrob Chemother. 2017;72:441\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"875_CR37","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1128\/AAC.00169-16","volume":"60","author":"A Belley","year":"2016","unstructured":"Belley A, Lalonde Seguin D, Arhin F, Moeck G. Comparative in vitro activities of oritavancin, dalbavancin, and vancomycin against methicillin-resistant Staphylococcus aureus isolates in a nondividing state. Antimicrob Agents Chemother. 2016;60:4342\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"875_CR38","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.2147\/DDDT.S313756","volume":"15","author":"M Gatti","year":"2021","unstructured":"Gatti M, Andreoni M, Pea F, Viale P. Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs. DDDT. 2021;15:3349\u201378.","journal-title":"DDDT"},{"key":"875_CR39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02280-18","author":"L Morata","year":"2019","unstructured":"Morata L, Cobo J, Fern\u00e1ndez-Sampedro M, et al. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. Antimicrobl Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.02280-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"875_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.2.655-656.2006","author":"DJ Skiest","year":"2006","unstructured":"Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol. 2006. https:\/\/doi.org\/10.1128\/JCM.44.2.655-656.2006.","journal-title":"J Clin Microbiol"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00875-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00875-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00875-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T04:13:30Z","timestamp":1698207210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00875-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["875"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00875-1","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"type":"print","value":"2193-8229"},{"type":"electronic","value":"2193-6382"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"11 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael J Rybak has received research grant support, consulted, or provided lectures for Allergan, Bayer, Merck, Spero, Melinta, and Paratek. Michael J Rybak is also supported in part by NIAID R01 AI12400. All other authors have no financial disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study has not received any funding from Allergan or any other company and the ethics committee approval was not required. Additionally, there were no human or animal subjects involved in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}